Drug intelligence / Profile preview

MPL-SE

Development stage: Unknown
Lead developer: Access to Advanced Health Institute
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular, Subcutaneous

Overview

MPL-SE is an adjuvant used in vaccine formulations, particularly for leishmaniasis vaccines. It consists of monophosphoryl lipid A (MPL) in a stable emulsion (SE). MPL-SE has been shown to enhance immune responses by directing them towards a Th1 profile, which is beneficial for protection against leishmaniasis. When combined with antigens such as Leish-111f or SMT (sterol 24-c-methyltransferase), it induces antigen-specific multifunctional CD4+ T cells capable of producing IFN-γ, IL-2, and/or TNF-α, which are associated with protection against leishmaniasis.

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on MPL-SE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MPL-SE.

Explore the full profile